Kras、Nras、Braf基因突变联合检测在转移性大肠癌中的意义

发布时间：2018-03-05 04:30

本文选题：大肠癌　切入点：Kras　出处：《广东医学》2017年02期 　论文类型：期刊论文

【摘要】：目的探讨大肠癌Kras、Nras、Braf基因突变与临床病理特征及预后的意义。方法应用实时荧光定量PCR Taq Man探针法检测90例大肠癌患者Kras、Nras、Braf基因突变。结果 90例大肠癌标本中33例(36.7%)检测到Kras12、13、61密码子基因突变,4例(4.4%)检测到Nras12、13、61密码子基因突变,6例(6.7%)检测到Braf V600E基因突变。在有无淋巴结转移及远处转移的患者,Kras基因突变差异有统计学意义(醊2=7.220、8.720,P0.01)。在不同的性别、年龄、肿块大小、浸润深度、分化程度,Kras基因突变均差异无统计学意义(P0.05)。Kras、Nras、Braf基因野生型患者的3年生存率均高于突变型(P0.01),无淋巴结转移和远处转移组患者的3年生存率明显高于伴淋巴结转移和远处转移组(P0.01)。Kras与Nras、Braf基因突变无明显负相关性。结论联合检测Kras、Kras、Braf基因突变对转移性大肠癌的治疗及预后评估具有重要的意义。
[Abstract]:Objective to investigate the clinical and pathological features and prognostic significance of the mutations in the Taq gene of Krascoid Nrascogene in colorectal cancer. Methods the mutation of Krasn Nrasnar Braf gene in 90 patients with colorectal cancer was detected by real-time fluorescence quantitative PCR Taq Man method. Results 33 of 90 colorectal cancer specimens were examined. The mutation of Braf V600E gene was detected in 6 cases (6 cases). The mutation of Braf V600E gene was significantly different in patients with lymph node metastasis and distant metastasis (P < 0.05). 2 / 7.220 / 8.720 / P0.01. in different genders, Age, mass size, depth of invasion, The 3-year survival rate of the wild-type patients with Kras gene mutation was higher than that of the mutant type P0.01. the 3-year survival rate of the patients with lymph node metastasis and distant metastasis was significantly higher than that of the patients with lymph node metastasis. There was no significant negative correlation between the mutation of nrastir Braf gene and P0.01n.Kras in distant metastasis group. Conclusion the combined detection of Kraslus krasu Braf gene mutation is of great significance in the treatment and prognosis evaluation of metastatic colorectal cancer.
【作者单位】：无锡市第二人民医院病理科;
【分类号】：R735.34

【参考文献】